Critical analysis of prostate-specific antigen doubling time calculation methodology

Cancer

Volumn 106, Issue 5, 2006, Pages 1047-1053

  Svatek, Robert S ^a   Shulman, Michael ^a   Choudhary, Pankaj K ^b   Benaim, Elie ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS AT DALLAS   (United States)

Author keywords

Doubling time; Prostate carcinoma; Prostate specific antigen; Random coefficient model

Indexed keywords

ANTIANDROGEN; BIOCHEMICAL MARKER; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANTIGEN SPECIFICITY; ARTICLE; CALCULATION; CANCER STAGING; CANCER SURVIVAL; DISEASE COURSE; HUMAN; MAJOR CLINICAL STUDY; MALE; METHODOLOGY; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; STATISTICAL ANALYSIS; TUMOR GROWTH;

AGED; AGED, 80 AND OVER; DISEASE PROGRESSION; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 33644502535     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.21696     Document Type: Article

References (27)

1. Stamey TA, Kabalin JN, McNeal JE, et al. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients. J Urol. 1989;141:1076-1083.
2. Carter HB, Pearson JD, Metter EJ, et al. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA. 1992;267:2215-2220.
3. Partin AW, Yoo J, Carter HB, et al. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol. 1993;150:110-114.
4. Schmid HP, McNeal JE, Stamey TA. Observations on the doubling time of prostate cancer. The use of serial prostate-specific antigen in patients with untreated disease as a measure of increasing cancer volume. Cancer. 1993;71:2031-2040.
5. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med. 1987;317:909-916.
6. D'Amico AV, Chen MH, Roehl KA, Catalona WJ. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med. 2004;351:125-135.
7. Stephenson AJ, Aprikian AG, Souhami L, et al. Utility of PSA doubling time in follow-up of untreated patients with localized prostate cancer. Urology. 2002;59:652-656.
8. D'Amico AV, Moul JW, Carroll PR, Sun L, Lubeck D, Chen MH. Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst. 2003;95:1376-1383.
9. D'Amico AV, Moul J, Carroll PR, Sun L, Lubeck D, Chen MH. Prostate specific antigen doubling time as a surrogate end point for prostate cancer specific mortality following radical prostatectomy or radiation therapy. J Urol. 2004;172 (5 Pt 2):S42-S46; discussion, S46-S47.
10. Schmid HP, Semjonow A, Maibach R. Prostate-specific antigen doubling time: a potential surrogate end point in hormone-refractory prostate cancer. J Clin Oncol. 1999;17:1645-1646.
11. Pruthi RS, Johnstone I, Tu IP, Stamey TA. Prostate-specific antigen doubling times in patients who have failed radical prostatectomy: correlation with histologic characteristics of the primary cancer. Urology. 1997;49:737-742.
12. Morrell CH, Pearson JD, Carter HB, Brant LJ. Estimating unknown transition times using a piecewise nonlinear mixed-effects model in men with prostate cancer. J Am Stat Assoc. 1995;90:45-53.
13. Leibman BD, Dillioglugil O, Scardino PT, et al. Prostate-specific antigen doubling times are similar in patients with recurrence after radical prostatectomy or radiotherapy: a novel analysis. J Clin Oncol. 1998;16:2267-2271.
14. Rabbani F, Perrotti M, Bastar A, Fair WR. Prostate specific antigen doubling time after radical prostatectomy: effect of neoadjuvant androgen deprivation therapy. J Urol. 1999;161:847-852.
15. Soergel TM, Koch MO, Foster RS, et al. Accuracy of predicting long-term prostate specific antigen outcome based on early prostate specific antigen recurrence results after radical prostatectomy. J Urol. 2001;166:2198-2201.
16. Bubley GJ, Carducci M, Dahut W, et al. Eligibility and response guidelines for Phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol. 1999;17:3461-3467.
17. Diggle P, Heagerty P, Liang KY, Zeger S. Analysis of longitudinal data, 2nd ed. New York: Oxford University Press, 2002.
18. Slate EH, Turnbull, BW. Statistical models for longitudinal biomarkers of disease onset. Stat Med. 2000;19:617-637.
19. Nagelkerke N. A note on a general definition of the coefficient of determination. Biometrika. 1991;78:691-692.
20. Shulman MJ, Benaim EA. The natural history of androgen independent prostate cancer. J Urol. 2004;172:141-145.
21. Ward JF, Blute ML, Slezak J, Bergstralh EJ, Zincke H. The long-term clinical impact of biochemical recurrence of prostate cancer 5 or more years after radical prostatectomy. J Urol. 2003;170:1872-1876.
22. Partin AW, Hanks GE, Klein EA, Moul JW, Nelson WG, Scher HI. Prostate-specific antigen as a marker of disease activity in prostate cancer [review]. Oncology (Williston Park). 2002;16:1218-1224; discussion, 1224, 1227-1228 passim.
23. Pauler DK, Finkelstein DM. Predicting time to prostate cancer recurrence based on joint models for non-linear longitudinal biomarkers and event time outcomes. Stat Med. 2002;21:3897-3911.
24. Cronin K, Slate EH, Turnbull, BW, Wells MT. Using the Gibbs sampler to detect changepoints: application to PSA as a longitudinal marker for prostate cancer. Comput Sci Stat. 1994;26:314-318.
25. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502-1512.
26. Scher HI, Steineck G, Kelly WK. Hormone-refractory (D3) prostate cancer: refining the concept. Urology. 1995;46:142-148.
27. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351:1513-1520.